1. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy;Schett;Nat Med,2013
2. The advent of biosimilar therapies in rheumatology—“O brave new world”;Scheinberg;Nat Rev Rheumatol,2012
3. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues;Lapadula;Clin Exp Rheumatol,2012
4. Congress of the United States of America. Patient protection and affordable care act, 〈http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf〉; 2010 [accessed 18.12.13].
5. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf〉; 2012 [accessed 21.05.14].